Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence and prevalence of IPF
3.2.1.2 Advancements in diagnostic techniques
3.2.1.3 Enhanced patient awareness of IPF
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment cost
3.2.2.2 Limited efficacy and side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Drug class
5.2.1 Antifibrotic agents
5.2.2 Anti-inflammatory
5.2.3 Corticosteroids
5.2.4 Immunosuppressants
5.2.5 Other drug classes
5.3 Therapy
5.3.1 Oxygen therapy
5.3.2 Pulmonary rehabilitation
5.4 Lung transplantation
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Adult
7.3 Geriatric
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals and clinics
8.3 Ambulatory surgical centers (ASCs)
8.4 Homecare settings
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Service Provider
10.1.1 Bumrungrad International Hospital
10.1.2 Cedars-Sinai
10.1.3 Cleveland Clinic
10.1.4 Dr. Sulaiman Al-Habib Medical Group
10.1.5 Nicklaus Children's Hospital
10.2 Medication Manufacturer
10.2.1 Boehringer Ingelheim International GmbH
10.2.2 Bristol-Myers Squibb Company
10.2.3 Cipla Inc.
10.2.4 F. Hoffmann-La Roche Ltd
10.2.5 FibroGen, Inc.
10.2.6 Galapagos NV
10.2.7 Liminal BioSciences Inc.
10.2.8 MediciNova, Inc.
10.2.9 Novartis AG
10.2.10 United Therapeutics
